Literature DB >> 2875808

Cumulative renal tubular damage associated with cisplatin nephrotoxicity.

M P Goren, R K Wright, M E Horowitz.   

Abstract

We assessed the acute and chronic effect of multiple courses of cisplatin therapy on renal tubules by monitoring the urinary excretion of alanine aminopeptidase, N-acetyl-beta-D-glucosaminidase, and total protein. Urine specimens were obtained before and after doses of cisplatin (90 mg/m2) given to 12 patients. Each dose of cisplatin induced transient increases in enzyme excretion, followed by proteinuria 3-5 days later. Transient enzymuria after the last cisplatin dose was significantly greater than that after the first dose. Moreover, persistent increases in urinary N-acetyl-beta-D-glucosaminidase and serum creatinine concentrations over pretherapy levels indicated chronic renal tubular damage. Our findings disclosed striking differences between patients in susceptibility to progressive nephrotoxicity.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2875808     DOI: 10.1007/bf00253068

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  42 in total

1.  Urinary excretion of alanine-aminopeptidase and N-acetyl-beta-D-glucosaminidase during sequential combination chemotherapy.

Authors:  U Diener; E Knoll; D Ratge; B Langer; H Wisser
Journal:  J Clin Chem Clin Biochem       Date:  1982-09

2.  Some effects of combination chemotherapy with cis-platinum on renal function in patients with nonseminomatous testicular carcinoma.

Authors:  S Meijer; D T Sleijfer; N H Mulder; W J Sluiter; J Marrink; H S Koops; T M Brouwers; J Oldhoff; G K van der Hem; E Mandema
Journal:  Cancer       Date:  1983-06-01       Impact factor: 6.860

3.  Disorders of serum electrolytes and renal function in patients treated with cis-platinum on an outpatient basis.

Authors:  G Giaccone; M Donadio; P Ferrati; L Ciuffreda; M Bagatella; M Gaddi; A Calciati
Journal:  Eur J Cancer Clin Oncol       Date:  1985-04

4.  Urinary excretion of N-acetyl-beta-D-glucosaminidase and alanine aminopeptidase in patients receiving amikacin or cis-platinum.

Authors:  U Diener; E Knoll; B Langer; H Rautenstrauch; D Ratge; H Wisser
Journal:  Clin Chim Acta       Date:  1981-05-05       Impact factor: 3.786

5.  Lack of age-dependent cisplatin nephrotoxicity.

Authors:  W J Hrushesky; W Shimp; B J Kennedy
Journal:  Am J Med       Date:  1984-04       Impact factor: 4.965

6.  The Coomassie Brilliant Blue method underestimates drug-induced tubular proteinuria.

Authors:  M P Goren; J T Li
Journal:  Clin Chem       Date:  1986-02       Impact factor: 8.327

7.  Hypomagnesemia after cisplatin combination chemotherapy.

Authors:  J E Buckley; V L Clark; T J Meyer; N W Pearlman
Journal:  Arch Intern Med       Date:  1984-12

8.  Acute response of urinary N-acetyl-beta-D-glucosaminidase to mannitol infusion in the dog.

Authors:  B H Brouhard; L Lagrone; J Rowe
Journal:  Am J Med Sci       Date:  1985-07       Impact factor: 2.378

9.  Proliferative lesions found in rat kidneys after a single dose of cisplatin.

Authors:  R E Bulger; D C Dobyan
Journal:  J Natl Cancer Inst       Date:  1984-11       Impact factor: 13.506

10.  Spectrophotometric assay for urinary N-acetyl-beta-D-glucosaminidase activity.

Authors:  E Horak; S M Hopfer; F W Sunderman
Journal:  Clin Chem       Date:  1981-07       Impact factor: 8.327

View more
  23 in total

Review 1.  Cisplatin nephrotoxicity. A review.

Authors:  G Daugaard; U Abildgaard
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Long-term renal follow-up of children treated with cisplatin, carboplatin, or ifosfamide: a pilot study.

Authors:  Kelly R McMahon; Maya Harel-Sterling; Michael Pizzi; Louis Huynh; Erin Hessey; Michael Zappitelli
Journal:  Pediatr Nephrol       Date:  2018-09-14       Impact factor: 3.714

Review 3.  Guidelines for treatment of renal injury during cancer chemotherapy 2016.

Authors:  Shigeo Horie; Mototsugu Oya; Masaomi Nangaku; Yoshinari Yasuda; Yasuhiro Komatsu; Motoko Yanagita; Yuko Kitagawa; Hiroyuki Kuwano; Hiroyuki Nishiyama; Chikashi Ishioka; Hiromasa Takaishi; Hideki Shimodaira; Akira Mogi; Yuichi Ando; Koji Matsumoto; Daisuke Kadowaki; Satoru Muto
Journal:  Clin Exp Nephrol       Date:  2018-02       Impact factor: 2.801

Review 4.  Treatments for astrocytic tumors in children: current and emerging strategies.

Authors:  Stanislaw R Burzynski
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

5.  Renal function following unilateral nephrectomy for neuroblastoma and Wilms' tumour.

Authors:  M Schell; P Cochat; A Hadj-Aïssa; E Bouffet; L Dubourg; M Brunat-Mentigny
Journal:  Pediatr Nephrol       Date:  1995-10       Impact factor: 3.714

6.  Urinary protein and enzyme excretion in patients receiving chemotherapy with the cis-platinum analogs carboplatin (CBDCA, JM8) and iproplatin (CHIP, JM9).

Authors:  A W Skillen; P K Buamah; B M Cantwell; C Cornell; A W Hodson; A L Harris
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

7.  Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicity.

Authors:  M P Goren; A A Forastiere; R K Wright; M E Horowitz; R K Dodge; B A Kamen; M J Viar; C B Pratt
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 8.  Drug-induced ototoxicity. Pathogenesis and prevention.

Authors:  M Y Huang; J Schacht
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Nov-Dec

9.  Evaluation of the effect of acetazolamide versus mannitol on cisplatin-induced nephrotoxicity, a pilot study.

Authors:  Manal El Hamamsy; Noha Kamal; Naglaa Samir Bazan; Mostafa El Haddad
Journal:  Int J Clin Pharm       Date:  2018-08-30

10.  The relative nephrotoxicity of cisplatin, cis-[Pt(NH3)2(guanosine)2]2+, and the hydrolysis product of cisplatin in the rat.

Authors:  M M Jones; M A Basinger; J A Beaty; M A Holscher
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.